June 24, 2013
/PRNewswire/ -- D
International, Inc. (OTCQX: DTRK), a leader in developing cloud-based,
® technologies and delivering related services for the clinical trials industry, today announced Intrasense (NYSE Alternext: ALINS) became the newest
™ Program member. Intrasense, a global leader in multimodal medical imaging software, develops and markets Myrian®, an advanced suite of applications for the review and analysis of medical images and the assessment of drug candidates efficacy in oncology and other pathologies.
, Intrasense's CEO, said, "We are proud to include DATATRAK in our international network of leading partners to extend our reach to the clinical trials market. The seamless combination of our innovative medical image reading and analysis solutions with
's technology will create additional value to clinical trials professionals."
"As the use of medical images in clinical trials continues to increase, doctors are seeking access to these images in context with the clinical data to provide faster, higher quality diagnoses," stated
Laurence P. Birch
's Chairman of the Board and CEO. "Partnering with Intrasense provides our clients access to advanced imaging technologies and a single source for collecting, viewing and cleaning clinical trial data. We continue to develop innovative solutions for accelerating cures."
™ Partner Program is collaboration between synergic companies to accelerate the drug development process. The program allows for extended service offerings to cover all areas of the drug development process with the goal of reducing study costs and furthering business development objectives.
™ Partner – Intrasense
Intrasense, a global leader in medical imaging software solutions, designs, develops and markets Myrian®, a unique software suite for the visualization and advanced processing of multimodal medical images (MRI, CT scans, PET, X-rays, etc.). Developed with leading academic partners, Myrian® combines and uses all of the various medical images to extract information that is vital to the patient's care, to the rapid appraisal of the efficacy of treatment and, therefore, to assessing drug candidates in oncology and other pathologies. With over 700 client sites around the world, Myrian® has been certified as a "medical device" in over 40 countries, in
the United States
. Intrasense SA is listed on NYSE Alternext (FR0011179886 – ALINS) and has offices in 9 countries.
International is a worldwide technology and services company delivering
® solutions and related services for the clinical trials industry.
built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via
's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The
™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world.
has offices located in
; and Cary (RTP),
. For more information, visit
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on
May 15, 2013
announcing its results for the first quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
SOURCE DATATRAK International, Inc.